Welcome to our dedicated page for Pediatrix Medical Group SEC filings (Ticker: MD), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Pediatrix Medical Group, Inc. filings document the public-company disclosures of a Florida physician-services operator focused on obstetrics, maternal-fetal medicine, neonatology and pediatric subspecialty care. Recent Form 8-K reports furnish operating results, including net revenue, earnings measures, same-unit revenue drivers, reimbursement factors, patient volume trends and hospital-based practice activity.
Proxy and governance filings cover director elections, shareholder voting results, executive compensation, pay-versus-performance data and the Pediatrix Medical Group, Inc. Second Amended and Restated 2008 Incentive Compensation Plan. Other material-event reports address board appointments, Regulation FD disclosures and common-stock repurchase authorizations.
Linynsky Laura A reported acquisition or exercise transactions in this Form 4 filing.
Pediatrix Medical Group director Laura A. Linynsky received a grant of 7,196 shares of restricted common stock as an annual equity award. The grant was made at no cash cost per share under the company’s Amended and Restated 2008 Incentive Compensation Plan. These restricted shares are scheduled to vest on May 7, 2027, meaning they become fully owned if service conditions are met. Following this award, Linynsky directly holds a total of 39,428 shares of Pediatrix Medical Group common stock.
SANSONE GUY P reported acquisition or exercise transactions in this Form 4 filing.
Pediatrix Medical Group director Guy P. Sansone received a grant of 7,196 shares of restricted common stock as an annual equity award. The shares were granted at no cash cost under the company’s Amended and Restated 2008 Incentive Compensation Plan and will vest on May 7, 2027. Following this award, Sansone directly holds 86,944 shares of Pediatrix Medical Group common stock, reflecting routine stock-based compensation rather than an open-market purchase or sale.
Young Sylvia Jean reported acquisition or exercise transactions in this Form 4 filing.
Pediatrix Medical Group director Sylvia Jean Young reported an equity award of common stock. She received 7,196 restricted shares of Pediatrix Medical Group, Inc. common stock on May 7, 2026, as a grant under the company’s Amended and Restated 2008 Incentive Compensation Plan in connection with her annual equity award.
The restricted shares were granted at no cash cost to her and will vest on May 7, 2027, subject to the plan’s terms. After this award, she now directly holds 47,814 shares of Pediatrix common stock, reflecting her ongoing equity-based compensation and alignment with shareholders.
Starcher John M. Jr. reported acquisition or exercise transactions in this Form 4 filing.
Pediatrix Medical Group director John M. Starcher Jr. received an equity grant of 7,196 shares of common stock as a compensation award. The shares were granted at no cash cost to him and increase his direct holdings to 73,260 shares.
These are restricted shares granted under the company’s Amended and Restated 2008 Incentive Compensation Plan in connection with an annual equity award. The restricted stock is scheduled to fully vest on May 7, 2027, meaning the shares become unrestricted for him on that date if vesting conditions are satisfied.
Weis Shirley A reported acquisition or exercise transactions in this Form 4 filing.
Pediatrix Medical Group director Shirley A. Weis received 7,196 restricted shares of common stock as an equity grant. The award was made at a price of $0.00 per share under the company’s Amended and Restated 2008 Incentive Compensation Plan in connection with her annual equity award.
These restricted shares are scheduled to vest on May 7, 2027. Following the grant, Weis directly holds 18,623 common shares and is also reported as an indirect owner of 36,028 common shares held by The Weis Family Trust, for which she and her husband serve as trustees and her immediate family members are beneficiaries.
McEachin Thomas reported acquisition or exercise transactions in this Form 4 filing.
Pediatrix Medical Group director Thomas McEachin reported an equity grant and updated holdings. He received a grant of 7,196 restricted shares of Common Stock at a price of $0.00 per share as an annual equity award under the Amended and Restated 2008 Incentive Compensation Plan. These restricted shares will vest on May 7, 2027. Following the grant, he directly holds 18,623 common shares. Separately, a trust titled the Thomas A. McEachin Living Trust dated April 17, 2025 holds 54,646 common shares, for which McEachin and his spouse serve as trustees and beneficiaries.
Newman Kurt Douglas reported acquisition or exercise transactions in this Form 4 filing.
Pediatrix Medical Group director Kurt Douglas Newman received a grant of 7,196 shares of restricted common stock as an annual equity award. The award was granted at no cash cost to him under the company’s Amended and Restated 2008 Incentive Compensation Plan and will vest on May 7, 2027. After this grant, he directly holds 16,933 Pediatrix common shares.
Pediatrix Medical Group, Inc. reported results from its 2026 Annual Shareholders’ Meeting. Shareholders approved the Second Amended and Restated 2008 Incentive Compensation Plan, increasing the number of common shares available for equity awards by 8,000,000 shares.
All director nominees were elected to serve until the 2027 Annual Shareholders’ Meeting, with each receiving over 69 million votes in favor, except one nominee who received lower support but was still elected. Shareholders also ratified PricewaterhouseCoopers LLP as independent auditor for the 2026 fiscal year and approved, on an advisory basis, executive compensation for 2025.
The meeting had strong participation, with 77,330,139 of 83,072,104 shares outstanding represented, constituting a quorum. The amended incentive plan and governance proposals are detailed further in the company’s previously filed proxy statement and attached exhibit.
Pediatrix Medical Group reported stronger quarterly results. Net revenue for the three months ended March 31, 2026 rose to $476.2 million from $458.4 million, driven mainly by a 2.8% increase in same-unit revenue and contributions from recent acquisitions.
Net income increased to $29.6 million from $20.7 million, with diluted EPS up to $0.36 from $0.24 and operating margin improving to 8.7% from 7.0%. Adjusted EBITDA grew to $58.2 million from $49.2 million. The company ended the quarter with $205.8 million in cash, no borrowings on its $450.0 million revolver, and completed a $7.9 million maternal-fetal medicine acquisition while repurchasing about 1.0 million shares for $19.9 million.
Pediatrix Medical Group reported stronger first quarter 2026 results, with net revenue of $476.2 million for the three months ended March 31, 2026, up from $458.4 million a year earlier. Earnings were $0.36 per diluted share, and Adjusted EPS, which excludes items such as amortization, stock-based compensation and transformational and restructuring expenses, was $0.44.
Net income was $30 million and Adjusted EBITDA reached $58 million. Same-unit revenue grew 2.8 percent, driven mainly by a 4.4 percent increase in same-unit revenue from net reimbursement-related factors, reflecting better cash collections, higher hospital contract administrative fees, higher patient acuity and a slightly favorable payor mix. Same-unit patient volume declined by 1.6 percent.
As of March 31, 2026, Pediatrix reported cash and cash equivalents of $205.8 million, total debt of $590.8 million and total shareholders’ equity of $878.6 million.